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ABSTRACT
Osteosarcoma occurs mostly in children and young adults, who are treated with 
multiple agents in combination with limb-salvage surgery. However, the overall 
5-year survival rate for patients with recurrent or metastatic osteosarcoma is 20-
30% which has not improved significantly over 30 years. Refractory patients would 
benefit from precise individualized therapy. We report here that a patient-derived 
osteosarcoma growing in a subcutaneous nude-mouse model was regressed by tumor-
targeting Salmonella typhimurium A1-R (S. typhimurium A1-R, p<0.001 compared to 
untreated control). The osteosarcoma was only partially sensitive to the molecular-
targeting drug sorafenib, which did not arrest its growth. S. typhimurium A1-R was 
significantly more effective than sorafenib (P <0.001). S. typhimurium grew in the 
treated tumors and caused extensive necrosis of the tumor tissue. These data show 
that S. typhimurium A1-R is powerful therapy for an osteosarcoma patient-derived 
xenograft model.
INTRODUCTION
The tumor-targeting amino-acid-auxotrophic 
strain Salmonella typhimurium (S. typhimurium) A1-R 
is attenuated by auxotrophic mutations for Arg and Leu 
[1]. S. typhimurium A1-R has also been selected for 
high tumor virulence in vivo. S. typhimurium A1-R has 
been shown to be effective against all major types of 
human cancer in nude mouse models including: cancers 
of the prostate [1–3], breast [4–6], pancreas [7–11], and 
ovary [12, 13], as well as soft tissue sarcoma [14, 15] 
and glioma [16, 17]. S. typhimurium A1-R was also 
effective against high-grade osteosarcoma, including 
lung metastasis [18], breast-cancer brain metastasis 
[19], and experimental breast-cancer bone metastasis 
[20] in orthotopic mouse models of human cancer 
cell lines. S. typhimurium A1-R was also shown to 
be effective on pancreatic cancer stem cells [9], and 
in combination with anti-angiogenic agents [11]. S. 
typhimurium A1-R was also effective against cervical 
cancer [21], melanoma [22], soft-tissue sarcoma [14], 
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and pancreatic cancer [10, 11] patient-derived 
orthotopic xenograft (PDOX) mouse models.
In recent studies, S. typhimurium A1-R was 
shown to be effective in a patient-derived orthotopic 
xenograft (PDOX) model of high-grade undifferentiated 
pleomorphic soft-tissue sarcoma (UP-STS) grown 
orthotopically in the right biceps femoris muscle of nude 
mice. Histological examination demonstrated eradication 
of the tumor treated with S. typhimurium A1-R followed 
by doxorubicin (DOX) [15].
S. typhimurium A1-R was also shown recently to 
be effective against a PDOX mouse model of follicular 
dendritic-cell sarcoma (FDCS) that was established in 
the biceps muscle of nude mice. The FDCS PDOX was 
resistant to both DOX and NVP-BEZ235 dactolisib 
(BEZ), but was sensitive to S. typhimurium A1-R [23].
Osteosarcoma occurs mostly in children and young 
adults [23, 24], who are treated with multiple agents in 
combination with limb-salvage surgery. However, the 
overall 5-year survival rate for patients with recurrent 
or metastatic osteosarcoma is 20-30%, which has not 
improved significantly over 30 years [25]. Refractory 
patients would benefit from precise individualized therapy.
In the present study, we used a patient-derived 
mouse xenograft model of osteosarcoma to demonstrate 
much higher efficacy of S. typhimurium A1-R administered 
by intratumor (i.t.) injection than the molecular-targeting 
drug, sorafenib.
RESULTS AND DISCUSSION
Comparison of the histology of the original 
patient tumor and mouse-grown patient tumor
Both the original patient tumor (Figure 1A) and 
the mouse-grown patient tumor (Figure 1B) contained 
neoplastic chondroid matrix occupied by anaplastic 
cells. Both the original patient tumor and the mouse-
grown patient tumor had hypercellular areas populated by 
anaplastic cancer cells displaying nuclear pleomorphism, 
coarse and hyperchromatic chromatin and abundant 
mitotic figures.
Intra-tumor administration of S. typhimurium 
A1-R was highly-effective, in contrast to 
sorafenib, in a patient-derived osteosarcoma 
xenograft model
Nude mice were randomized into 3 groups: 
untreated control; treated group with sorafenib (10 mg/
kg, p.o., 5 days a week, for 3 weeks); and treated with S. 
typhimurium A1-R (2.5×107 colony forming units [CFU], 
by intra-tumor [i.t.] injection, weekly, for 3 weeks). All 
tumors were measured twice a week.
Sorafenib significantly reduced tumor growth 
(P<0.001), but the tumors continued to grow (Figure 2). 
In contrast, tumors treated with S. typhimurium A1-R 
regressed and were significantly smaller than sorafenib-
treated tumors at the end of the study (P<0.001). Body 
weight range in all mice was from 26.6 to 31.1 g on day 
1. There was no significant difference in body weight 
between the control group and treated groups at any time 
points.
S. typhimurium A1-R growth in the treated 
tumors
S. typhimurium, expressing green fluorescent protein 
(GFP), was cultured in serial dilution from supernatants of 
tumor homogenates. Fluorescent bacteria were detected at 
all dilutions, indicating they were growing in the treated 
tumors (Figure 3).
Figure 1: Hematoxylin and eosin (H&E) staining of original patient tumor and mouse grown tumor. A. Original patient 
tumor (lung metastasis); B. Untreated patient tumor grown in nude mouse. Scale bars: 100 μm.
Oncotarget8037www.impactjournals.com/oncotarget
Figure 2: Intratumor (i.t.) administration of Salmonella typhimurium (S. typhimurium) A1-R regresses a patient-derived 
osteosarcoma xenograft model. Eighteen subcutaneous tumors in nude mice were randomized into 3 groups: untreated control (n = 6), 
treated group with sorafenib (n = 6; 10 mg/kg, p.o., 5 days a week, for 3 weeks), and treated with S. typhimurium A1-R (n = 6; 2.5 × 107 colony 
forming units [CFU], intratumoral injection, weekly, 3 weeks). All tumors were measured twice a week and tumor volume was calculated 
using the following equation: Tumor volume (mm3) = tumor length (mm) × tumor width (mm) × tumor width (mm) ×1/2. Both sorafenib and 
S. typhimurium A1-R effectively reduced tumor growth. In addition, tumors treated with S. typhimurium A1-R achieved regression and were 
significantly smaller than sorafenib-treated tumors. Body weight was not lost in any mice. *P < 0.001. Error bars: ± 1 SD.
Figure 3: Culture of S. typhimurium from treated tumors. Tumors were homogenized 48 hours after intra-tumor (i.t.) administration 
of S. typhimurium expressing GFP. Supernatants of the tumor homogenates were serially diluted and grown on agar medium for 12 hours 
and imaged with the OV100. Please see Materials and Methods. BF; bright field, GFP; green fluorescent protein. Scale bar: 10 mm.
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Effect of S. typhimurium on tumor histology
S. typhimurium caused extensive necrosis in the 
treated tumors as visualized in hematoxylin and eosin 
(H&E)-stained tumors (Figure 4).
Sorafenib, a multi-kinase inhibitor that blocks 
VEGFR, PDGFR, MAPK, and KIT, was previously 
shown to have efficacy against recurrent or un-resectable 
osteosarcoma as well as metastatic or recurrent 
angiosarcoma in Phase II clinical studies [26, 27].
S. typhimurium A1-R, in addition to being 
effective against the major types of human cancer 
in orthotopic nude mouse models [1–17, 21, 22], has 
been shown to be effective in patient-derived models 
of pancreatic cancer [10, 11], soft-tissue sarcoma [14, 
15, 23] and melanoma [22]. In the present study, we 
now show that S. typhimurium A1-R could regress an 
osteosarcoma in a patient-derived model in contrast to 
sorafenib which could not.
Future experiments will examine efficacy 
of S. typhimurium A1-R against PDOX models of 
osteosarcoma and then in patients. Recently, the tumor-
targeting obligate anaerobe Clostridium novyi NT has 
shown efficacy in leiomyosarcoma patients treated i.t. 
[28]. Bacterial therapy of cancer, after 80 years, has 
returned to the clinic [29].
Our group has developed many mouse models 
and treatment strategies for osteosarcoma [18, 30–38]. 
Bacterial therapy maybe the most efficacious.
Bacteria have important advantages for the treatment 
of cancer. Many bacteria naturally target tumors and they 
can be genetically-manipulated to improve selective tumor 
targeting and to reduce infection of normal tissue. Bacteria 
can directly kill infected cancer cells and possibly enhance 
immune effects against the tumor, even when tumors are 
drug resistant. Bacteria can grow in, and are not readily 
cleared from, infected tumors. In addition, bacterial 
targeting may not be limited by poor tumor vasculature 
[29].
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [39–44].
Figure 4: Effect of S. typhimurium on tumor histology. Tumors were resected from nude mice at autospy, fixed in formalin, 
embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E) by standard methods. The figure shows the histology of an 
osteosarcoma treated with S. typhimurium A1-R. Necrotic areas are indicated by yellow arrows. Scale bar: 100 μm.
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MATERIALS AND METHODS
Mice
Athymic nu/nu male nude mice (AntiCancer Inc., 
San Diego, CA), 4-6 weeks old, were used in this study. 
All animal studies were conducted with an AntiCancer 
Institutional Animal Care and Use Committee (IACUC)-
protocol specifically approved for this study, which 
described the duration of the experiment, the frequency of 
animal monitoring, the survival aspects of the study, and 
any anticipated maximum tumor volume or weight loss 
thresholds at which animals would be euthanized, and in 
accordance with the principals and procedures outlined in 
the Guide for the Care and Use of Laboratory Animals, 8th 
edition, under PHS Assurance Number A3873-1. Animals 
were anesthetized by subcutaneous injection of a 0.02 ml 
solution of 80-100 mg/kg ketamine, 10 mg/kg xylazine, 
and 3 mg/kg acepromazine maleate. Ibuprofen (7.5 mg/
kg orally in drinking water every 24 hours for 7 days 
post-surgery) was used in order to provide analgesia post-
operatively in the surgically-treated animals.
Patient-derived tumor
The study was reviewed and approved by the UCLA 
Institutional Review Board (IRB #10-001857) before the 
study began. Written informed consent was obtained 
from the patient as part of the above-mentioned UCLA 
Institutional Review Board-approved protocol. A 16-year 
old patient with localized left distal femoral high-grade 
osteosarcoma underwent limb salvage distal femoral 
replacement. One year later, three bilateral metachronous 
pulmonary metastases appeared. The patient was 
treated with curative surgery at the Division of Surgical 
Oncology, University of California, Los Angeles (UCLA). 
The patient received chemotherapy using methotrexate, 
cisplatinum and doxorubicin (MAP) peri-operatively.
Establishment of a mouse model of osteosarcoma 
by subcutaneous transplantation
A fresh sample of the osteosarcoma metastasized 
to the lung was obtained and transported immediately 
to the laboratory at AntiCancer, Inc., on wet ice. The 
sample was cut into 5 mm fragments and implanted 
subcutaneously in nude mice [15]. Implanted tumors were 
established in 4 weeks. The established tumor was cut into 
5 mm fragments, then these fragments were implanted 
subcutaneously to the flank in nude mice for the treatment 
study.
Preparation and administration of 
S. typhimurium A1-R
GFP-expressing S. typhimurium A1-R bacteria 
(AntiCancer, Inc., San Diego, CA, USA) were grown 
overnight on LB medium and then diluted 1:10 in LB 
medium. Bacteria were harvested at late-log phase, 
washed with PBS, and then diluted in PBS [1, 3, 4].
Bacterial culture
To demonstrate bacterial viability in the treated 
tumor, a subcutaneous xenograft mouse model was used. 
Forty-eight hours after S. typhimurium A1-R i.t. injection 
(2.5 × 107 CFU in 50 μl PBS), the treated tumor was 
homogenized, then suspended in PBS (phosphate-buffered 
saline, Corning, New York, NY). The suspension was 
serially diluted, then cultured in LB agar for 12 hours. 
GFP-expressing colonies of S. typhimurium A1-R were 
detected by the OV100 Small Animal Imaging System 
(Olympus, Tokyo, Japan) [45].
Treatment protocol
Ten days after implantation, tumors reached 9 
mm in diameter. Tumor-bearing mice were randomized 
into the following 3 groups of 6 mice each: G1, control 
without treatment (n=6); G2, treated with S. typhimurium 
A1-R (2.5 × 107 CFU in 50 μl PBS, i.t. injection), once 
a week, for 3 weeks (n=6); G3, treated with sorafenib 
(Selleckchem, Houston, TX, S7397), 10 mg/kg, p.o., 5 
days a week, for 3 weeks (n=6). Tumor length, width 
and mouse body weight were measured twice in a 
week. Tumor volume was calculated with the following 
formula: Tumor volume (mm3) = length (mm) × width 
(mm) × width (mm) × 1/2. Data are presented as mean ± 
SD. When a tumor was not detectible, the tumor response 
was considered as complete remission. All treated mice 
were sacrificed on day 25, and tumors were resected for 
further histological evaluation [15].
Histological examination
Fresh tumor samples were fixed in 10% formalin 
and embedded in paraffin before sectioning and staining. 
Tissue sections (5 μm) were deparaffinized in xylene and 
rehydrated in an ethanol series. Hematoxylin and eosin 
(H &E) staining was performed according to standard 
protocols. Histological examination was performed 
with a BHS System Microscope (Olympus Corporation, 
Tokyo, Japan). Images were acquired with INFINITY 
ANALYZE software (Lumenera Corporation, Ottawa, 
Canada) [15].
Statistical analysis
SPSS statistics version 21.0 was used for all 
statistical analyses (IBM, New York City, NY, USA). 
Significant differences for continuous variables were 
determined using the Student’s t-test. A probability value 
of P < 0.05 was considered statistically significant [15].
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